First time available for research use


Durvalumab antibody from Imfinzi®

Therapeutic PD-L1-antibody from the original Imfinzi® commercial drug targeting the PD-L1-antigen, also referred to as Imfinzi® or durvalumab antibody. Research-relevant quantities are available as licence-free consumable in an aliquoted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments, biosimilar developers can order different batches at the same time.

Choose your antibody
Easy Access

Easy Access

Easy to order as license-free research consumable
Multiple batches

Multiple batches

Up to 10 batches of original drugs for examining batch-to-batch variations
Reduce costs

Reduce costs

Up to 80% less compared to the original pharmaceutical price
Prompt delivery

Prompt delivery

Shipment within days worldwide according to GDP-standards
Documented origin

Documented origin

Information on batch, registration number, expiry date, GDP-compliant pedigree

What our clients say

Durvalumab / Imfinzi

Product Reference

Drug nameImfinzi®
API typeDurvalumab is a human monoclonal gG1κ antibody directed against the immunomodulatory cell surface ligand protein PD-L1 and produced in Chinese hamster ovary cells by recombinant DNA technology.
Pharmacotherapeutic group
Antineoplastic agents, monoclonal antibodies
ATC code
Target of antibody
PD-L1; Synonyms: CD274, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, A530045L16Rik, B7h1, Pdcd1l1,
Pdcd1lg1, Pdl1, RGD1566211
General functionIMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose
disease has not progressed following platinum-based chemoradiation therapy. (Source EMA , package leaflet)
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Expression of programmed cell death ligand-1 (PD-L1) protein is an adaptive immune response that
helps tumours evade detection and elimination by the immune system. PD-L1 can be induced by
inflammatory signals (e.g., IFN-gamma) and can be expressed on both tumour cells and
tumour-associated immune cells in tumour microenvironment. PD-L1 blocks T-cell function and
activation through interaction with PD-1 and CD80 (B7.1). By binding to its receptors, PD-L1 reduces
cytotoxic T-cell activity, proliferation and cytokine production.
Durvalumab is a fully human, immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that
selectively blocks the interaction of PD-L1 with PD-1 and CD80 (B7.1). Durvalumab does not induce
antibody dependent cell-mediated cytotoxicity (ADCC). Selective blockade of PD-L1/PD-1 and
PD-L1/CD80 interactions enhances antitumour immune responses and increases T-cell activation.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against programmed death ligand 1 (PD-L1). Avelumab binds PD-L1 and blocks the interaction between PD-L1 and the programmed death 1 (PD-1) and B7.1 receptors. This removes the suppressive effects of PD-L1 on cytotoxic CD8+ T-cells, resulting in the restoration of anti-tumour T-cell responses.
Avelumab has also shown to induce natural killer (NK) cell-mediated direct tumour cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC).
Original license holder
Marketing authorisation numbers
Marketing authorisation holder
AstraZeneca AB
SE-151 85 Södertälje
Name of the manufacturer of the biological active substance
AstraZeneca Pharmaceuticals LP
Frederick Manufacturing Center (FMC)
633 Research Court
Frederick, Maryland 21703 United States
Name and address of the manufacturer(s) responsible for batch releaseMedImmune UK Ltd
6 Renaissance Way
L24 9JW
United Kingdom


MedImmune Pharma B.V.
Lagelandseweg 78
6545CG Nijmegen,
Max shelf life
36 months
Storage conditions
2°C – 8°C
List of excipients
Histidine hydrochloride monohydrate
Trehalose dihydrate
Polysorbate 80
Water for injections